Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AstraZeneca
FDA approves Atacand for use with an ACE inhibitor to treat heart failure
June 15th, 2005
AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved a new use for its angiotensin receptor blocker (ARB) Atacand (candesartan cilexetil) tablets for the treatment of heart failure (NYHA class II-IV) in patients with left ventricular systolic dysfunction (ejection fraction less than or equal to 40%) to reduce cardiovascular death and to reduce heart failure hospitalizations. Atacand also has an added effect on these outcomes when used with an angiotensin-converting enzyme (ACE) inhibitor. Atacand is, according to the company, now the first ARB proven to provide these benefits with or without an ACE inhibitor and is the...
Source: Physician Law Weekly (2005-06-15)
|
